3 results
Approved WMOCompleted
The proportion of patients in GC-free remission after 20 weeks.
Approved WMORecruiting
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.
Approved WMORecruiting
The purpose of this study is to demonstrate the efficacy of 9-valentextraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared toplacebo in the prevention of the first invasive extraintestinal pathogenicEscherichia coli disease (IED)…